Tasly Biopharma ranks second in the 2019 Future Healthcare VB 100 -Top 100 China Innovative Medicine List

Tasly Biopharma ranks second in the 2019 Future Healthcare VB 100 -Top 100 China Innovative Medicine List

On December 20, 2019, the 2019 Future HealthCare VB 100 was held in Beijing with the theme of “New Life Increment”. This conference focused on multiple factors such as policy environment, technological environment and demand space to comprehensively interpret future development trend of the health industry. Tasly Biopharma ranked second in the “2019 Future Healthcare VB 100-Top 100 China Innovative Medicine List” in this conference.

2019 Future Healthcare VB 100-Top 100 China Innovative Medicine List

 

Future Healthcare VB 100 List (VB100) is the first domestic innovative medical and health list for non-listed companies jointly launched by VCBeat and VCBeat Research in 2015. It aims to select Chinese innovative companies that truly represent the future of medical care, to discover the core strength of future medical and health industry, and to promote the innovation and reform of the medical and health industry.

2019 Future Healthcare VB 100 List has optimized and upgraded the structure and content of the list based on the experience in the past few years. 2019 Future Healthcare VB 100 List consists of five main lists and 18 sub-lists, covering the four major fields of medical services, innovative devices, digital medicine, and innovative medicine, as well as dozens of subdivisions such as third-party medical imaging centers, mental health, electronic medical records, surgical robots and rehabilitation equipment.

The list is mainly selected and based on the company’s latest round of valuation, combined with the company’s patents, product development, core team, partners, industry structure, corporate reputation and other aspects.

(Source:Takara )

Source |Excerpted from VCBeat